Desirox纳入医保了吗？

In 2010, it was approved for marketing in China and is approved for the treatment of chronic iron overload caused by frequent blood transfusions in beta-thalassemia patients aged 2 years and above, and for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndrome aged 10 years and above.

Desirox is clinically used for patients with iron accumulation due to the need for long-term blood transfusion (such as those with thalassemia or other rare anemias). It is a new type of ferric iron chelator with high oral absorption rate. The drug metabolism half-life is 8 to 16 hours, reaching the blood peak at 24 hours. The concentration reaches a stable state after 3 days. After metabolism, it is mainly excreted in the feces.

So, is Desirox included in medical insurance?

It is understood that Desirox is currently on the market in China, but it is not included in domestic medical insurance. The price of Enrig after it is launched in China is relatively high, with a box price of about $2,000. A normal person weighing 60kg would cost more than 24,000$ to take Enrige for a month. It can be seen that it is difficult for ordinary families to accept this price and cannot afford it! 

Novartis of Switzerland imports Enrig in India, the specification is 400mg*30 tablets/box, and the price is about $700. 

The specification of Enriga produced by Indian pharmaceutical factory is 500*30 tablets/box, and the price is about 500$. Due to the fluctuation of exchange rate, the price will be different. Please consult the medical companion tour for the specific price! 

In addition, long-term blood transfusion can easily lead to secondary iron overload. Iron overload refers to the pathological phenomenon of excessive iron deposition in human tissues and organs, leading to cell damage and organ dysfunction. Iron overload can cause damage to cardiovascular, endocrine, liver, kidney, nervous system, etc., leading to various diseases and serious harm. Iron chelators can effectively increase iron excretion, reduce iron content in the body and its pathological deposition in various organs. They are currently the only effective drugs for the treatment of iron overload.